Basic Info.
Function
Antibiotic and Antimicrobial Agents
Certification
GMP, Reach, FDA, USP Ep
Grade Standard
Medicine Grade
Suitable for
Elderly, Adult
Trademark
China Sinopharm
Transport Package
25 Kg/Drum
Product Description
99% purity Azithromycin CAS 83905-01-5 USP/EP/CEP/FDA Azithromycin is an antibiotic used for the treatment of a number of bacterial infections.This includes middle ear infections, strep throat, pneumonia, traveler's diarrhea, and certain other intestinal infections. It can also be used for a number of sexually transmitted infections, including chlamydia and gonorrhea infections.Along with other medications, it may also be used for malaria. It can be taken by mouth or intravenously with doses once per day.
Product Name: | Azithromycin |
CAS: | 83905-01-5 |
MF: | C38H72N2O12 |
MW: | 748.98 |
Melting point | 113-115°C |
storage temp. | Store at -20°C |
Stability: | Stable. Incompatible with strong oxidizing agents. |
CAS DataBase Reference | 83905-01-5(CAS DataBase Reference) |
Hazardous Substances Data | 83905-01-5(Hazardous Substances Data) |
1.UsageBecause the side effects of Azithromycin are less than Cephalosporins, now Azithromycin is the most commonly used antibiotics for bacterial infection-related diseases in our hospital clinic. This drug is a second generation semi-synthetic derivative of macrolide, whose structure is different from Erythromycin. It inserted a methyl-substituted nitrogen in 9a site of Erythromycin lactone ring, generating a 15-membered ring macrolide.
The mechanism of action of Azithromycin is similar to Erythromycin. By binding to 50S subunit susceptible ribosome, Azithromycin inhibits protein synthesis which depends on RNA to show an antibacterial effect, retaining the antibacterial spectrum of typical Erythromycin. As for activity to chlamydia, Azithromycin is similar to Erythromycin. Compared with Erythromycin, antibacterial activity for gram-negative bacteria has been significantly improved, antibacterial activity for Haemophilus influenzae and Neisseria gonorrhoeae is more four times than Erythromycin, antimicrobial activity for Legionella bacteria is more about 2 times than Erythromycin, and antibacterial activity for Enterobacteriaceae is significantly stronger than Erythromycin. The MIC of most gram-negative bacteria is less than 1μg/ml. Staphylococcus aureus and Streptococcus pyogenes show cross-resistance on Azithromycin and Erythromycin. For toxoplasmosis and syphilis, Azithromycin also has a good role in the killing. Azithromycin is mainly used for respiratory tract infections, genitourinary tract infections, skin and soft tissue infections and sexually transmitted diseases which are caused by sensitive bacteria.
2.PharmacokineticsIt is rapidly absorbed after oral administration, and its bioavailability is 37%. After a single oral dose of 0.5g, the peak time is 2.5 to 2.6 hours, peak plasma concentration (Cmax) is 0.4~0.45mg/L. This product is widely distributed in the body, and concentrations in each tissue are up to 10 to 100 times of the blood concentration over the same period. The plasma concentrations are high in macrophages and fibroblasts , the former can transport Azithromycin to inflammation sites. After a single dose administration of the product, elimination half-life of plasma concentration is 35 to 48 hours, more than 50% of the administered dose is excreted in the bile duct in original shape, and after 72 hours administration about 4.5% is excreted in the urine in original shape. With increasing plasma concentrations, serum protein binding rate of this product decreased. When the plasma concentration is 0.02 μg/mL, serum protein binding rate is 15%; when the blood concentration is 2 μg/mL, serum protein binding rate is 7%.
3.Antibacterial spectrum1. Gram-positive aerobic bacteria, such as Staphylococcus aureus, Streptococcus pyogenes (A group β-hemolytic streptococcus), Streptococcus pneumoniae, α-hemolytic Streptococci (Streptococcus viridans group) and the other Streptococcus, Diphtheria (rodlike) bacteria.
2. Gram-negative aerobic bacteria, such as Haemophilus influenzae, Haemophilus parainfluenza, catarrhal bacteria, Acinetobacter, Yersinia, Legionella spp, Bordetella pertussis, parapertussis, Shigella, Pasteurella spp., Vibrio cholerae, Vibrio parahaemolyticus, Shiga topiramate o Aeromonas. The activities for Escherichia coli, Salmonella enteritidis, Salmonella typhi, Enterobacter, addicted to waterborne Aeromonas and Klebsiella are not the same, and sensitivity test is needed.
3. Anaerobic bacteria, such as Bacteroides spp., Clostridium perfringens, Lactococcus digestion, digestion Streptococcus, Fusobacterium, Propionibacterium acnes.
4. Sexually transmitted disease microorganisms, such as Chlamydia trachomatis, Treponema pallidum, Neisseria gonorrhoeae, Haemophilus Duke.
5. Other microorganisms, such as Borrelia burgdorferi (Lyme pathogens), Chlamydia pneumoniae, Mycoplasma hominis, Ureaplasma urea, bending genus, mononucleosis and Lee de bacilli.
Azithromycin shows cross-resistance for Gram-positive bacteria with Erythromycin-resistant and various strains of Staphylococcus aureus with methicillin-resistant, and Gram-positive bacteria such as Proteus, Serratia, Morgan bacteria, Pseudomonas aeruginosa are usually resistant to Azithromycin.
Address:
No. 293 Jiang Ning Road, Shanghai, China
Business Type:
Manufacturer/Factory, Trading Company
Business Range:
Health & Medicine
Management System Certification:
ISO 9001
Company Introduction:
China Sinopharm International (Shanghai) Co., Ltd. is a comprehensive commercial service enterprise centering international pharmaceutical business. It is a wholly-owned subsidiary under China Sinopharm International Corporation and is affiliated to China National Pharmaceutical Group Corporation (referred to as "Sinopharm Group"), a Fortune Global 500. Founded in 1985, the company has an net asset of nearly 200 million yuan. It has complete commercial facilities and 23, 000 square meters of properties including an office building and shopping malls in Shanghai′s West Nanjing Road commercial area and multiple warehouses. International business are carried out based on the platforms of Sinopharm Group and Sinopharm International Pharmaceutical and aims to spread China′s high-quality pharmaceutical products and services to the world. Through close cooperation with major domestic pharmaceutical companies, high-quality pharmaceutical products and overall solutions are provided to overseas customers. We are a well-known pharmaceutical enterprise in China with partners extending to more than 80 countries and regions around the world. We have long been focusing on the field of medicine and health. Our main business covers overseas registration and import and export of pharmaceutical products such as preparations, APIs, medical devices and diagnostic reagents; Export of pharmaceutical engineering equipment, production lines and technical services; Import and export of health products, food additives and plant extracts. In 2017, the company′s total import and export volume exceeded 300 million yuan. At present, we have obtained more than 20 overseas registration certificates for preparations, APIs and medical devices and assisted many domestic pharmaceutical companies for access to the international market. Over the years, the company has always adhered to idea to be "professional, efficient, cohesive, progressive" and undertakes the mission to "create value, serve for customers and cultivate employees". Our strategic goal is to place customers as our center and become a world-class pharmaceutical import and export enterprise.